Please assess the completion status of the following clinical trial:

Trial Title: Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with \>= 70% carotid stenosis (unilateral or bilateral) who are scheduled to undergo elective carotid endarterectomy~* Age \>= 18 years~* Agreement of the operating surgeon for patient to participate~Exclusion Criteria:~* Surgery scheduled \< 14 days after randomization~* Pregnancy~* ALT, GGT \> 3x upper limit of normal (ULN)~* Creatinine \> 3.5 mg/dL~* Prior intolerance to statins~* Reluctance to add or change dosage of statin therapy during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Fasudil hydrochloride (Type: EXPERIMENTAL): Fasudil hydrochloride 40 mg three times a day X 14 days
- Drug: Placebo oral tablet (Type: PLACEBO_COMPARATOR): Placebo 1 tablet three times daily x 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).